Market Size of Traveler's Diarrhea Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 6.80 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Traveler's Diarrhea Treatment Market Analysis
The traveler's diarrhea treatment market is expected to register a CAGR of 6.8% during the forecast period.
The pandemic caused unprecedented disruption in the tourism industry, with a massive fall in international demand amid widespread lockdowns and travel restrictions by countries to contain the spread of the virus, which impacted the traveler's diarrhea market. For instance, according to the World Tourism Organization (UNWTO), in 2022, the pandemic caused a 72% decline in international tourist arrivals in 2020 and 71% in 2021. Thus, a decrease in tourism significantly impacted the market's growth. However, the market is currently growing at a stable pace due to the resumption of tourism. According to the World Tourism Organization, tourism doubled in 2022. It is expected to witness a similar trend over the coming years. Thus, the market is expected to gain traction over the coming years because of declining COVID-19 cases and increased tourism.
Traveler's diarrhea affects millions of international travelers traveling to developing countries yearly. Food and contaminated water are the primary sources of infection. Bacteria, such as E. coli and Salmonella, are the common causes of traveler's diarrhea. According to the UNWTO, between January and September 2022, a projected 700 million tourists traveled abroad, more than double (+133%) the number seen during the same period in 2021. In addition, Europe took the lead in the recovery of global travel, with numbers 81% higher than before the pandemic. Between January and September 2022, international arrivals to the Middle East increased by 225%. The prevalence of traveler's diarrhea is higher among travelers visiting regions in South Asia and Southeast Asia. The travel destination is the most significant risk factor for traveler's diarrhea.
According to the article published in the June 2021 issue of the National Library of Medicine, traveler's diarrhea is a common ailment in individuals traveling to resource-limited destinations overseas. It is estimated to affect nearly 40-60% of travelers and is the most common travel-associated condition. Thus, the significant burden of traveler's diarrhea is expected to boost the demand for its treatment, thereby boosting the market's growth.
Hence, owing to these factors, the market is likely to witness significant growth during the forecast period. However, the side effects associated with the drugs are expected to impede the market's growth.
Traveler's Diarrhea Treatment Industry Segmentation
As per the scope of the report, traveler's diarrhea is a digestive tract disorder characterized by an intestinal infection that occurs when a person consumes contaminated food and water.
The traveler's diarrhea treatment market is segmented by drug type (antibiotics, anti-diarrheal, and other drug types), distribution channel (hotel pharmacies, retail pharmacies, and other distribution channels), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD million) for the above segments.
| By Drug Type | |
| Antibiotics | |
| Anti-diarrheal | |
| Other Drug Types |
| By Distribution Channel | |
| Hospital Pharmacies | |
| Retail Pharmacies | |
| Other Distribution Channels |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Traveler's Diarrhea Treatment Market Size Summary
The traveler's diarrhea treatment market is poised for significant growth, driven by the resurgence of global tourism following the pandemic's impact on travel. The market is experiencing a stable recovery as international travel resumes, with regions like Europe and the Middle East leading the recovery. Traveler's diarrhea remains a prevalent issue for millions of international travelers, particularly those visiting developing countries, due to contaminated food and water. The condition is primarily caused by bacteria such as E. coli and Salmonella, and its high prevalence among travelers is expected to boost the demand for effective treatments. Despite the challenges posed by drug side effects, the market is anticipated to expand as the burden of traveler's diarrhea continues to drive the need for antibiotic treatments.
North America holds a significant share of the traveler's diarrhea treatment market, supported by a strong presence of manufacturers and increasing awareness of available treatments. The United States, in particular, is witnessing a rise in international and domestic travel, which is likely to contribute to the market's growth. Strategic activities by key market players, including product launches and partnerships, are expected to further propel the market. Companies such as Bausch Health Companies Inc., Immuron Limited, and others are actively involved in advancing treatment options, with recent approvals and patents enhancing their market positions. These factors collectively suggest a promising outlook for the traveler's diarrhea treatment market over the forecast period.
Traveler's Diarrhea Treatment Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Surge in the Number of Travelers
-
1.2.2 Rising Awareness Among Travelers About Hygiene, Food, and Water Safety
-
1.2.3 Availability of Over-the-counter Medications
-
-
1.3 Market Restraints
-
1.3.1 Side Effects Associated with the Drugs
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Drug Type
-
2.1.1 Antibiotics
-
2.1.2 Anti-diarrheal
-
2.1.3 Other Drug Types
-
-
2.2 By Distribution Channel
-
2.2.1 Hospital Pharmacies
-
2.2.2 Retail Pharmacies
-
2.2.3 Other Distribution Channels
-
-
2.3 By Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Traveler's Diarrhea Treatment Market Size FAQs
What is the current Traveler's Diarrhea Treatment Market size?
The Traveler's Diarrhea Treatment Market is projected to register a CAGR of 6.80% during the forecast period (2024-2029)
Who are the key players in Traveler's Diarrhea Treatment Market?
Bausch Health Companies Inc. (Salix Pharmaceuticals), Cosmo Pharmaceuticals N.V., Johnson & Johnson, Pfizer Inc. and Procter & Gamble are the major companies operating in the Traveler's Diarrhea Treatment Market.
